Increasing incidences of coagulation disorders, Venous Thromboembolism: a key driver to promote the growth in the heparin market

Pune, India -- (SBWire) -- 02/05/2018 --The report "Heparin Market by treatment type (unfractionated heparin, low molecular weight heparin (LMWH) and ultra-molecular weight heparin (UMWH), by route of administration (IV injection, subcutaneous injection), by applications, (Clinical trials, medical devices and venous Thromboembolism), by end user (hospital, blood and steam banks and others), and by region (North America, Europe, Asia-Pacific and RoW)", the Heparin market is expected to reach USD 13.44 billion by 2023 expanding at a CAGR of 5.91% between 2017 and 2023.

Some of the key driving factors attributing to the growth of this market include Increasing incidences of coagulation disorders, Venous Thromboembolism, Deep Vein Thrombosis and heart diseases. Thromboembolism (VTE), rise in the prevalence of the obesity, and growing geriatric population.

Get Sample Copy of this Report: https://www.infiniumglobalresearch.com/Reports/MakeSampleRequest/120

Increasing incidences of coagulation disorders, Venous Thromboembolism: a key driver to promote the growth in the heparin market

Disorders of platelet count or function, disorders of clotting and combination of both these are three types of bleeding disorders. Coagulation disorders are the failure of the ability of body in controlling the blood clotting. Coagulation disorderscan lead to hemorrhage or thrombosis. Hemophilia, Von Willebranddisease, clotting factor deficiencies, liver disease, overdevelopment of circulating anticoagulants vitamin k deficiency and platelet dysfunction are some of the major causes of coagulation disorders. Venous thromboembolisimis a major medical condition after heart attack and stroke in USA. It is a kind of blood clot that occur in veins. Deep vein thrombosis occur in deep veins in leg , arm or other veins. When DVT clot moves to lungs and stops blood supply, it causes pulmonary embolism. Cancer, immobilization, surgery and hospitalization are major reasons for occurrence of DVT and PE. Among women, pregnancy, usage of hormones can lead to these conditions. According to World Health organization almost 17.7 million people died due to cardiovascular diseases in 2015. It is around 31% of overall global deaths. The incidences of heart diseases are increasing considerably. Many of the medical conditions are inter-related. Due to disorderly lifestyle, obesity and other factors the incidences of these medical conditions are increasing. Moreover, the people in old age are susceptible to some of these medical conditions.

10 million Venous Thrombosis Embolism cases occur worldwide. It causes lot of disabilities and death worldwide. Most of the cases are undocumented in low-income and other developing countries. In USA and Europe, this account for more deaths when compared to number of deaths related to breast cancer, accidents, prostrate cancer and AIDS.

Sanofi the largest player in fragmented heparin market worldwide

The global heparin market was fragmented in nature over the period of 2015 and 2016. Sanofi accounted for the 26.2% share to be the largest company in the world heparin market. Moreover, large players look to acquire other companies to consolidate their market position. The heparin market has experienced over 65% incidences of M&A and Joint ventures or collaborations as expansion strategies.

Browse Research Report: https://www.infiniumglobalresearch.com/healthcare_medical_devices/global_heparin_market

North America is the largest Heparin market

The global heparin market was dominated by North America, accounting for USD 3499.2 million in 2016, and it is projected to reach USD 5066.8 million in 2023, growing at a CAGR of 5.45% between 2017 and 2023. Asia-Pacific heparin market is expected to growth a CAGR of 7.18 % over the forecast period 2017 to 2023.

Companies profiled in the report

The report profiles some of the key companies in the Heparin market include Sanofi SA, Glaxo

SmithKline plc, Pfizer, Inc.Leo Pharma, Dr. Reddy's Laboratories, Fresenius SE & Co. KG, Teva Pharmaceutical Industries Ltd., Baxter International, and Aspen Holdings.

About Infinium Global Research
Infinium Global Research and Consulting Solutions is started with a single motto of being business partner of first choice. We at Infinium work on the strengths of our clients to ensure we help them consolidate their market position. We firmly believe in the fact that 'if you are able to develop newer opportunities then you find there is no dearth of opportunities for you. With our strategic research approaches and deep dive in the market segments, we try to find out new opportunities that our clients can encash with their existing resources. Our experts with over 100 years of cumulative experience in research offer the best in the industry services to our clients to ensure that they achieve their business goals.